Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of mycobacterium abscessus in the presence of inducible Erm(41)

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2606-2611

  Maurer, Florian P ^a   Rüegger, Vera ^a   Ritter, Claudia ^a   Bloemberg, Guido V ^a   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cystic fibrosis; Drug susceptibility; Methylase; Rapidly growing mycobacteria

Indexed keywords

BACTERIAL PROTEIN; CLARITHROMYCIN; METHYLTRANSFERASE; RNA 23S; RRL PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENES, RRNA; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; SEQUENCE ANALYSIS, DNA;

EID: 84867622981     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks279     Document Type: Article

References (35)

1. Wallace RJ Jr. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, M. fortuitum and M. chelonae. Clin Chest Med 1989; 10: 419-29.
2. Cullen AR, Cannon CL, Mark EJ et al. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J Respir Crit Care Med 2000; 161: 641-5.
3. Olivier KN, Weber DJ, Lee JH et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167: 835-40.
4. Olivier KN, Weber DJ, Wallace RJ Jr. et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 828-34.
5. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
6. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716-46.
7. Sanguinetti M, Ardito F, Fiscarelli E et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39: 816-9.
8. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
9. Griffith DE. The talking Mycobacterium abscessus blues. Clin Infect Dis 2011; 52: 572-4.
10. Jarand J, Levin A, Zhang L et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52: 565-71.
11. Jeon K, Kwon OJ, Lee NY et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896-902.
12. Brown BA, Wallace RJ Jr, Onyi GO et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-4.
13. Mushatt DM, Witzig RS. Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin Infect Dis 1995; 20: 1441-2.
14. Sander P, Prammananan T, Meier A et al. The role of ribosomal RNAs in macrolide resistance. Mol Microbiol 1997; 26: 469-80.
15. Pfister P, Jenni S, Poehlsgaard J et al. The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059. J Mol Biol 2004; 342: 1569-81.
16. Akshay S, Bertea M, Hobbie SN et al. Phylogenetic sequence variations in bacterial rRNA affect species-specific susceptibility to drugs targeting protein synthesis. Antimicrob Agents Chemother 2011; 55: 4096-102.
17. Pfister P, Corti N, Hobbie S et al. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A_G. Proc Natl Acad Sci USA 2005; 102: 5180-5.
18. Böttger EC, Springer B, Prammananan T et al. Structural basis for selectivity and toxicity of ribosomal antibiotics. EMBO Rep 2001; 2: 318-23.
19. Meier A, Kirschner P, Springer B et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994; 38: 381-4.
20. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995; 39: 2625-30.
21. Wallace RJ Jr., Meier A, Brown BA et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-81.
22. Nash KA, Andini N, Zhang Y et al. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother 2006; 50: 3476-8.
23. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
24. Bastian S, Veziris N, Roux AL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-81.
25. Adékambi T, Berger P, Raoult D et al. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56: 133-43.
26. Adékambi T, Colson P, Drancourt M. rpoβ-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol 2003; 41: 5699-708.
27. Mollet C, Drancourt M, Raoult D. rpoB sequence analysis as a novel basis for bacterial identification. Mol Microbiol 1997; 26: 1005-11.
28. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
29. Zhang Y, Rajagopalan M, Brown BA et al. Randomly amplified polymorphic DNA PCR for comparison of Mycobacterium abscessus strains from nosocomial outbreaks. J Clin Microbiol 1997; 35: 3132-9.
30. Liu M, Douthwaite S. Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA. Antimicrob Agents Chemother 2002; 46: 1629-33.
31. Madsen CT, Jakobsen L, Buriánková K et al. Methyltransferase Erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis. J Biol Chem 2005; 280: 38942-7.
32. Madsen CT, Jakobsen L, Douthwaite S. Mycobacterium smegmatis Erm(38) is a reluctant dimethyltransferase. Antimicrob Agents Chemother 2005; 49: 3803-9.
33. Nash KA, Zhang Y, Brown-Elliott BA et al. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005; 55: 170-7.
34. Sander P, Springer B, Prammananan T et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002; 46: 1204-11.
35. Shcherbakov D, Akbergenov R, Matt T et al. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77: 830-40.